NeuBase Makes Strategic Move; EZ Detect's Expanded Reach Fuels Biomerica
- August 03rd, 2023
- 504 views
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced a pause in its program development. Instead, NeuBase will explore strategic options, including acquisitions, mergers, and other transactions, with the goal of maximizing shareholder value.
According to the company, the outcome of this evaluation process remains uncertain, and there is no guarantee that any particular course of action will be taken.
$NBSE was trading at $1.26 in pre-market, up $0.02 (+1.61%).
In other news, Biomerica, Inc. (Nasdaq: BMRA) said that CVS Pharmacy has initiated the nationwide rollout of the Company's EZ Detect colorectal disease screening test across more than 7,000 CVS Pharmacy locations.
The EZ Detect product is expected to be available for purchase starting September, following its distribution to CVS Health centers. Moreover, Biomerica is collaborating with CVS Health to introduce another of its products in CVS pharmacies.
In pre-market, $BMRA was trading at $2.00, reflecting a gain of $0.54 (+36.98%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login